Citi Downgrades Several Life Science Tools Vendors, Citing End Market Concerns | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Citi Investment Research & Analysis today downgraded a number of life science tools firms saying end market weakness is expected to continue through 2012.

In a research report, analyst Amit Bhalla said the academic/government market will face pressure while pharma/biotech will see headwinds for the next year, limiting growth opportunities for tools vendors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.